ELIGARD (leuprolide acetate) is indicated for the palliative due to incorrect reconstitution or administration of the product (see Monitoring and Laboratory .. Gently insert the long, white replacement plunger rod into the gray. PACKAGE LEAFLET: INFORMATION FOR THE USER. ELIGARD 45 mg powder and solvent for solution for injection. Leuprorelin acetate. Read all of this leaflet. Eligard® is a sterile polymeric matrix formulation of leuprorelin acetate for subcutaneous package insert for constitution and administration procedures.
|Published (Last):||26 October 2011|
|PDF File Size:||16.50 Mb|
|ePub File Size:||4.87 Mb|
|Price:||Free* [*Free Regsitration Required]|
Use these drugs together cautiously and with close monitoring. Major Avoid coadministration of vandetanib with leuprolide due to an increased risk of QT prolongation and torsade de pointes TdP. Visually inspect leuprolide acetate injection for particulate matter and eligqrd prior to administration whenever solution and container permit. A thin layer of powder on the wall of the syringe packwge normal; the diluent supplied should appear clear. May adjust dose if changes in body weight occur.
An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib if QT prolongation packzge. Moderate Loperamide should be used cautiously and with close monitoring with leuprolide. The suspension should appear milky. Clinically relevant QTc prolongation may occur with deutetrabenazine.
If vemurafenib and another drug associated with a possible risk for QT prolongation and torsade de pointes TdP must be coadministered, ECG monitoring is recommended; closely monitor the patient for QT interval prolongation. Voriconazole has been associated with QT prolongation and rare cases of torsades de pointes. Use leuprolide with caution in patients with depression and emotional instability; monitor patients for worsening of psychiatric symptoms during treatment with leuprolide.
Asenapine might also decrease the clinical response to leuprolide. Drugs with a possible risk for QT prolongation and Inaert that should be used cautiously and with close monitoring with leuprolide include ketoconazole.
Consider whether the benefits of androgen deprivation treatments e. Withhold HCG administration in cases where the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome OHSS.
Eligard (leuprolide acetate) dose, indications, adverse effects, interactions from
Cases of QT prolongation and TdP have been reported during postmarketing use of fluvoxamine. Patients with urinary tract obstruction or metastatic vertebral lesions should be monitored carefully for signs of renal impairment or spinal cord compression, respectively, during initial leuprolide treatment.
At this time, there are no known comparable studies evaluating the risk of cardiovascular events in women or children taking GnRH agonists for other indications. The correct dose of leuprolide for the treatment of neoplastic disease will vary from protocol to protocol.
Oops Something Went Wrong!
Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with leuprolide include atomoxetine. Tricyclic antidepressants TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy insrrt serum concentrations. Major Concomitant use of ziprasidone and leuprolide should be avoided due to the potential for additive QT prolongation.
Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin. The Viadur implant and Eligard brands of leuprolide are contraindicated in females due to due to a lack of indication for use and limited experience, thus these products would not be given to the lactating female.
Severe Mesoridazine carries a known risk for QT prolongation and torsade de pointes TdPand is contraindicated for use with other medications that may prolong the QT interval. Minor In the absence of relevant data and as a precaution, paciage that cause hyperprolactinemia, such as cimetidine, should not be administered concomitantly with gonadotropin releasing hormone analogs since hyperprolactinemia down-regulates the number of pituitary GnRH receptors.
Moderate There may be an increased risk for QT prolongation and torsade de pointes TdP during concurrent use of fluvoxamine and leuprolide. The co-administration of panobinostat with leuprolide is not recommended; QT prolongation has been reported with both agents.
When vardenafil 10 inaert was given with another drug that is known to cause QT prolongation, an additive effect on the QT interval was observed. Androgen deprivation therapy prolongs the QT interval. Because of the adverse reaction profile e. Moderate There may be an increased risk for QT prolongation and torsade de pointes TdP during concurrent use of mirtazapine and leuprolide.
An ECG should also be performed at least 2, 12, and 24 weeks after starting bedaquiline therapy. Leuprolide injection contains benzyl alcohol; the depot formulation and implant do not. Consider ECGs and close clinical monitoring if co-use of such drugs is medically necessary.
Major Citalopram causes dose-dependent QT interval prolongation.
Major Avoid coadministration of lenvatinib with leuprolide due to the risk of QT prolongation. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with leuprolide include anagrelide. Major The concomitant use of midostaurin and leuprolide may lead to additive QT interval prolongation.
Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: Drugs with a possible risk for QT prolongation that should be eligrad cautiously and with close monitoring with citalopram include leuprolide. Major Avoid coadministration of ribociclib with leuprolide due to an increased risk for QT prolongation. After injection, withdraw the needle from the injection site.